Targeted Oncology Staff

Discover the latest breakthroughs in oncology from major conferences, including significant findings in breast cancer and multiple myeloma treatments.

During a live event, Jan Drappatz, MD, surveyed participants on the rationale for their choice of treatment for a 39-year-old patient with grade 2 astrocytoma.

During a live event, Yelena Y. Janjigian, MD, moderated a discussion on how to use PD-L1 CPS status when considering immunotherapy for gastric cancer.

During a live event, Moshe C. Ornstein, MD, MA, discussed the recommended regimens for non–clear cell renal cell carcinoma and evaluated the findings on dual immunotherapy in this setting.

Discover the latest breakthroughs in oncology, including FDA approvals, innovative trials, and highlights from the upcoming ASH Annual Meeting.

During a live event, Joshua K. Sabari, MD, discussed outcomes of the phase 3 IMforte trial in extensive-stage small cell lung cancer.

During a live event, Praneeth Baratam, MBBS, discussed long-term data from a trial comparing luspatercept with epoetin alfa in low-risk myelodysplastic syndromes.

During a live event, Thomas G. Martin, MD, discussed the importance of controlling disease and avoiding barriers to access so patients with multiple myeloma can receive CAR T-cell therapy.

November 2025 marks a transformative month for oncology, featuring groundbreaking FDA approvals that enhance treatment options across various cancer types.

During a live event, Yelena Y. Janjigian, MD, moderated a discussion on which frontline treatment to give a 60-year-old patient with stage IV gastric adenocarcinoma.

During a live event, Praneeth Baratam, MBBS, discussed the molecular factors that affect staging of lower-risk myelodysplastic syndromes.

Discover the latest advancements in oncology, including groundbreaking treatments for breast cancer, gastroesophageal cancer, and neurofibromatosis.

During a live event, Hannah Choe, MD, discussed options for steroid-resistant cGVHD based on organ involvement, efficacy, and safety profiles.

During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens for non–clear cell renal cell carcinoma.

Discover the latest advancements in oncology, including FDA approvals, groundbreaking trial results, and expert insights shaping cancer treatment today.

During a live event, Mazyar Shadman, MD, MPH, discussed zanubrutinib’s long-term outcomes in CLL for high-risk patients.

During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.

During a live event, Anthony B. El-Khoueiry, MD, discussed nivolumab plus ipilimumab vs lenvatinib/sorafenib in unresectable HCC.

During a live event, Che-Kai Tsao, MD, MS, and participants considered the tolerability and efficacy benefits of high starting doses vs dose escalation with TKIs in renal cell carcinoma.

Discover the latest breakthroughs in oncology, including FDA approvals, practice-changing trials, and insights on global cancer research disparities.

During a live event, Lori Wirth, MD, discussed preferred treatment for thyroid cancer with and without a RET, NTRK, or ALK fusion.

During a live event, Wade T. Iams, MD, MSCI, discussed potential ways to determine which patients benefit most from additional therapy for extensive-stage small cell lung cancer.

During a live event, Cora N. Sternberg, MD, discussed tolerability outcomes from the ARANOTE trial and distinguishing aspects of androgen receptor pathway inhibitors.

During a live event, Randy F. Sweis, MD, and participants discussed treating non–clear cell renal cell carcinoma based on current data and particular challenges facing patients.

October 2025 marked a pivotal month in oncology with multiple FDA approvals and designations, enhancing treatment options for various cancers.

Discover the latest breakthroughs in oncology, including FDA designations and promising trial results that could transform cancer treatment.

During a live event, Mazyar Shadman, MD, MPH, discussed options for a patient with high-risk CLL as recommended by the NCCN guidelines.

During a live event, Che-Kai Tsao, MD, MS, and participants gave their reasoning for their choice of combination therapy for a 65-year-old patient with high-burden metastatic renal cell carcinoma.

During a live event, Hannah Choe, MD, and event participants discuss steroid-dependent chronic GVHD, favoring adding therapy over increasing steroids.

During a live event, Cora N. Sternberg, MD, discussed the development of androgen receptor pathway inhibitors and takeaways from the ARANOTE trial in hormone-sensitive prostate cancer.